Yelena Y Janjigian, ASCO 2021: Durvalumab in Gastric Cancer and the MATTERHORN Study
touchONCOLOGY joins Dr Yelena Janjigian (Medical Oncologist, Chief, Memorial Sloan Kettering Cancer Center, New York, NY, USA) at ASCO 2021 to discuss durvalumab in gastric cancer and the MATTERHORN study.
The abstract ‘A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03) (NCT04379596)’ (abstract number TPS261) was presented at the 2021 ASCO Annual Meeting.
Citation: J Clin Oncol 39, 2021 (suppl 3; abstr TPS261)
1. What is the rationale for the addition of durvalumab to neoadjuvant-adjuvant FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer? (00:15-01:45)
2. What are the eligibility criteria and key inclusion criteria for the MATTERHORN study? (01:45-04:30)
3. Could you give us a brief overview of the study design? (04:30-06:26)
4. What are the primary and secondary study endpoints? (06:26-06:50)
5. When are initial results expected? (06:50-07:10)
Disclosures: Research Funding: NCI, Department of Defense, Cycle for Survival, Fred’s Team, RGENIX, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly and Merck. Advisory Boards/Consulting: Bristol-Myers Squibb, Merck Serono, Merck, Eli Lilly, Daiichi-Sankyo, Pfizer, Bayer, Imugene, AstraZeneca, Zymeworks Inc., Seattle Genetics, Basilea Pharmaceutica, RGENIX (stock options and consulting).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.
Filmed in coverage of the 2021 ASCO Annual Meeting.
Share this Video
Related Videos In Gastrointestinal Cancers
Michael Pishvaian, AACR 2023: TIGeR-PaC phase III trial, intra-arterial gemcitabine for patients with locally advanced pancreatic cancer
Treatment of locally advanced pancreatic cancer has really primarily consisted of systemic intravenous chemotherapy. The TIGeR-PaC trial is aiming to assess if an alternative treatment mode, intra-arterial delivery of gemcitabine, improves overall survival. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the […]
Michael Pishvaian, AACR 2023: Challenges in the treatment of locally advanced pancreatic cancer
Locally advanced pancreatic cancer represents around 30% of all newly diagnosed pancreatic cancers and can be challenging to treat. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the challenges in the treatment of locally advanced pancreatic cancer. Dr Pishvaian presented an abstract […]
Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!